Journal of clinical medicine

Updated Overview of Treatments for Transthyretin Amyloid Heart Disease

Updated

Abstract

Transthyretin stabilizers and RNA silencers improve survival, functional capacity, and quality of life in patients with ATTR-CM.

  • ATTR-CM is caused by the misfolding and deposition of transthyretin protein.
  • Current treatments include TTR stabilizers like tafamidis and acoramidis and TTR silencers such as vutisiran.
  • Early-phase studies of gene-editing and monoclonal antibody therapies show promising amyloid-lowering effects.
  • Standard therapies continue to be TTR stabilizers and silencers, with gene-editing and monoclonal antibodies being explored as future options.
  • The emergence of various therapies suggests potential for targeted, personalized medicine in treating ATTR-CM.

Simplified

Key numbers

30%
Mortality Reduction
Reduction in all-cause mortality with tafamidis vs. placebo
80.7%
Survival Rate
Survival at 30 months for acoramidis vs. placebo
0.72
Hazard Ratio
Hazard ratio for mortality in vutrisiran group vs. placebo

Full Text

What this is

  • Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart condition caused by misfolded transthyretin protein.
  • Recent advancements have introduced several novel therapies, transforming ATTR-CM from a largely untreatable condition to a manageable disease.
  • Current treatments include transthyretin stabilizers like tafamidis and acoramidis, and silencers such as vutisiran, which aim to halt disease progression.
  • Emerging therapies, including gene-editing techniques and monoclonal antibodies, show promise for future treatment options.

Essence

  • ATTR-CM, once difficult to treat, now has multiple therapeutic options that improve survival and quality of life. Current therapies focus on stabilizing transthyretin and silencing its production, with ongoing research into innovative treatments.

Key takeaways

  • Tafamidis significantly reduces all-cause mortality by 30% and cardiovascular-related hospitalizations by approximately 30% in patients with ATTR-CM compared to placebo.
  • Acoramidis shows 80.7% survival at 30 months, compared to 74.3% in the placebo group, indicating its potential as an effective treatment for ATTR-CM.
  • Vutrisiran significantly reduces mortality with a hazard ratio of 0.72, demonstrating its efficacy in treating both wildtype and variant ATTR-CM.

Caveats

  • Limited long-term data on new therapies raises questions about their durability and safety in broader populations.
  • Some trials, like patisiran for ATTR-CM, were not approved due to insufficient evidence of meaningful clinical outcomes.

Simplified

Funding

Competing interests

S.P. reports consulting and speaker’s bureau income from Alnylam, Pfizer, Astra-Zeneca, and BridgeBio.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free